Acta Cardiologica Sinica is a distinguished journal dedicated to the advancement of cardiology and cardiovascular medicine, published by the Taiwan Society of Cardiology. Since its inception in 1988, this journal has provided a platform for researchers and clinicians to share cutting-edge findings and insights into cardiac health, cardiovascular diseases, and innovative treatment strategies. With an impressive Q3 classification in the Cardiology category for 2023, the journal is recognized for its contributions to the field, ranked #208 out of 387 in Scopus, placing it within the 46th percentile of medical journals. Although it currently does not offer open access options, it remains a valued resource for the global cardiovascular community. The journal's commitment to disseminating high-quality research papers, reviews, and case studies ensures that it plays a vital role in improving cardiovascular health practices and outcomes. For researchers, professionals, and students alike, Acta Cardiologica Sinica is essential reading for staying informed about the latest developments in cardiology.

TEXAS HEART INSTITUTE JOURNAL, published by the renowned Texas Heart Institute, stands as a pivotal resource in the field of cardiology and cardiovascular medicine. With a history spanning over four decades since its establishment in 1982, this journal addresses a wide range of topics within its scope, including clinical studies, innovative treatments, and groundbreaking research in heart health. Despite its Q3 ranking in both Cardiology and Cardiovascular Medicine, the journal is committed to fostering advancement in medical knowledge and practice, providing an essential platform for healthcare professionals and researchers alike. While currently lacking open access, the journal is recognized for its contributions to the field, aiming to illuminate critical healthcare discussions and promote the exchange of ideas. For those interested in staying at the forefront of cardiovascular research, TEXAS HEART INSTITUTE JOURNAL offers invaluable insights and the latest developments shaping the future of heart care.

JACC: CardioOncology, published by Elsevier, is a pioneering open-access journal that has been at the forefront of the intersection between cardiology and oncology since its inception in 2019. With a focus on innovative research aimed at understanding the cardiovascular implications of cancer therapies, it has swiftly achieved recognition, holding a prestigious Q1 category ranking in both Cardiology and Cardiovascular Medicine and Oncology as of 2023. The journal's high impact factor and notable Scopus rankings—20th out of 387 in Cardiology and 44th out of 404 in Oncology—underscore its essential role in disseminating cutting-edge findings that inform clinical practices and improve patient outcomes. JACC: CardioOncology aims to provide a comprehensive platform for researchers, healthcare professionals, and students to share and access vital information, facilitating collaborations that advance knowledge in this critical field. With its commitment to open access, the journal ensures that groundbreaking research is readily available to a global audience, fostering an inclusive environment for academia and practice alike.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

Cardiovascular Endocrinology & Metabolism is a leading open-access journal dedicated to advancing our understanding of the interconnections between cardiovascular health and endocrine functions. Published by Lippincott Williams & Wilkins, this journal serves as a vital resource for researchers and clinicians alike, providing timely insights into the intricate relationships between metabolic disorders and cardiovascular diseases. With an impressive impact factor and categorized in Q2 for both Cardiology and Cardiovascular Medicine as well as Endocrinology, Diabetes, and Metabolism, it holds a significant position within its respective fields. The journal has been fully open access since its inception in 2012, ensuring that critical research is accessible to a global audience. By fostering innovation and collaboration, Cardiovascular Endocrinology & Metabolism aims to promote better health outcomes and stimulate novel research directions, making it an essential resource for professionals striving to bridge the gaps between these two critical domains.

Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.

HEART FAILURE REVIEWS is a premier academic journal published by Springer, dedicated to the dynamic field of cardiology and cardiovascular medicine. With an impressive Q1 ranking in 2023, the journal stands as a vital resource for researchers, clinicians, and students seeking to stay abreast of the latest developments in heart failure management and research. Covering a broad spectrum of topics, including innovative therapies, epidemiology, and pathophysiology of heart failure, it fosters an environment for interdisciplinary collaboration. The journal is indexed with an ISSN of 1382-4147 and an E-ISSN of 1573-7322, ensuring widespread dissemination of knowledge. Although it does not currently offer open access options, its rigorous peer-review process guarantees high-quality content that contributes significantly to the scientific community. Established in 1996 and running through 2024, HEART FAILURE REVIEWS continues to be a leading platform for advancing understanding and treatment of heart conditions, making it an indispensable resource for all stakeholders in cardiac health.

Expert Review of Anticancer Therapy, published by Taylor & Francis Ltd, is a distinguished journal focusing on the dynamic and ever-evolving field of oncology and pharmacology. Since its inception in 2001, this journal has played a pivotal role in disseminating critical reviews and analyses of novel anticancer therapies, fostering a deeper understanding among researchers and practitioners alike. With an impressive categorization in the 2023 Q2 quartiles for both Oncology and Pharmacology, it ranks #98 out of 272 in Pharmacology and #165 out of 404 in Oncology according to Scopus metrics, placing it well within the upper echelons of academic journals. The journal’s rigorous peer-review process ensures high-quality publications that are integral for advancing cancer research and therapeutic strategies. Although currently not an open access journal, it aims to bridge the gap between scientific discovery and clinical application, making it an essential resource for anyone involved in the fight against cancer.

Current Cardiology Reports, published by Springer, is a leading peer-reviewed journal dedicated to advancing the field of cardiology and cardiovascular medicine. With its ISSN 1523-3782 and E-ISSN 1534-3170, the journal offers a platform for researchers and practitioners to share innovative research findings, clinical insights, and comprehensive reviews, contributing to the ongoing dialogue in cardiovascular health. Recognized for its high impact, Current Cardiology Reports holds a prestigious Q1 ranking in the Cardiology category for 2023 and ranks #83 out of 387 in Scopus, placing it in the 78th percentile among journals in its field. The journal, converging its insights from 1999 to 2024, aims to disseminate valuable knowledge that can inform clinical practice and influence future research directions. Although not an Open Access journal, the rich content and timely articles published within its pages are invaluable to both seasoned professionals and emerging scholars in cardiology. Based in New York, United States, the journal continues to play a critical role in shaping cardiovascular medicine through rigorous scientific inquiry and education.

Revista de la Federacion Argentina de Cardiologia is a vital publication in the field of Cardiology and Cardiovascular Medicine, providing a platform for researchers and healthcare professionals to share significant findings and innovative concepts since its inception in 2012. Published by the Federacion Argentina Cardiology, this journal specifically addresses contemporary issues and advancements within cardiology, contributing to the scholarly dialogue essential for improving cardiovascular health. Despite being categorized in the Q4 quartile for 2023 and presently ranking #358 out of 387 in its field, the journal remains committed to fostering academic inquiry and disseminating valuable research for both local and global audiences. Although it is not an open-access journal, it strives to balance accessibility with rigorous academic standards, ensuring quality contributions that are critical for practitioners and students alike. The journal’s ongoing evaluation and adaptation in the ever-evolving landscape of cardiology underscore its importance in advancing cardiovascular science and practice.